A Phase 1 interventional study of XKH001 Injection in Asthma Patients, sponsored by Zhejiang Kanova Biopharmaceutical Co., LTD. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-17.
Sponsored by Zhejiang Kanova Biopharmaceutical Co., LTD · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.
Among the 251 studies in Asthma with a site in China, this one is the 178th largest by enrollment of the 182 interventional ones that give a count, is one of 23 that started in 2023, is one of 31 in phase 1, and was the 190th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in China, United States, Argentina and 2 more countries
Ages 18–85
AstraZeneca · Sites in China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–70
Shanghai Pulmonary Hospital, Shanghai, China · Sites in China
Ages 18+
Chiesi Farmaceutici S.p.A. · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
251 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 46 · Phase 3 50 · Phase 4 18
First in 1998; this study’s year is marked. 23 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 203 across the 182 interventional studies, 407 across the 69 observational. Of the 116 that completed or were terminated, 30 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
140 of 251 have an industry lead sponsor. The 10 most frequent:
Zhejiang Kanova Biopharmaceutical Co., LTD is the lead sponsor of 6 studies on the registry; 4 are open to participants now.
Zhejiang Kanova Biopharmaceutical Co., LTD has 1 study filed under Asthma — fewer than ten, so there is no comparison to draw.
28 of the studies in Asthma with a site in China that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06323213Phase 3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Efficacy and Safety Study of 610 in Patients With Severe Asthma | 2027-02 |
| NCT06895460Phase 3The First Affiliated Hospital with Nanjing Medical UniversityA Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets) | 2027-06-30 |
| NCT06653322Phase 3Guangdong Hengrui Pharmaceutical Co., LtdA Multi-centered,Randomized,Double-blind,Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma | 2027-09 |
| NCT06471257Phase 3AstraZenecaA Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma | 2027-10-04 |
| NCT06307665Phase 3AstraZenecaEvaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | 2027-10-13 |
Add all 28 to your calendar (.ics) → With an account.
Among the 251 studies in Asthma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a single-arm, open-label clinical study. A total of 12 patients with allergic asthma are planned to be enrolled to receive XKH001 600 mg Q4W administration for the assessment of the safety, immunogenicity, PK, and PD characteristics of multiple doses.
This study is a single-arm, open-label clinical study. A total of 12 patients with allergic asthma are planned to be enrolled to receive XKH001 600 mg Q4W administration for the assessment of the safety, immunogenicity, PK, and PD characteristics of multiple doses.
The screening period will not be more than 28 days (i.e., 4 weeks). The treatment period will be 12 weeks, and the follow-up period will be 12 weeks.
All recruited patients with allergic asthma will undergo various screening procedures within 28 days prior to the first dose, and those who pass the screening will be sequentially enrolled.
Patients who are enrolled in the study will be admitted to the study site on the day before each scheduled dose (D-1, D28, and D56) to complete the necessary pre-dose safety assessments and receive XKH001 subcutaneous (SC) injections on D1, D29, and D57.
The patient will undergo regular safety assessment procedures (AE/SAE, vital signs, physical examination, laboratory tests, 12-lead electrocardiogram (ECG), etc.), FeNO, pulmonary function tests (FEV1 PD20 Mch), sputum induction, and other blood sample collections (PK, PD, and ADA) during the treatment period (D1-D85) and the subsequent 12-week follow-up period (\~D169).
Visits and procedures at screening, treatment, and follow-up are detailed in the Schedule of Assessment.
If a subject discontinues treatment prematurely, the "Early Withdrawal" visit and all procedures will be performed, the same as D169.
If asthmatic patients test positive for seasonal allergens (such as pollen), they should avoid the allergy season when enrolling in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible to participate in the study, a subject must meet all of the following criteria:
Subjects diagnosed with asthma according to the Guidelines for the Prevention and Treatment of Bronchial Asthma (China) 2020 with an asthma course (since the first incidence) of at least 6 months and meet the following requirements at the same time:
Subjects with a positive reaction to at least 1 type of aeroallergen (such as dust mites, pollen, mold, or animal hair) in the skin prick test or allergen-specific IgE testing record before screening or during screening; Subjects with the (ULN) at the site ≤ total serum IgE ≤ 1000 IU/mL at screening; Subjects with the bronchial provocation test PD20 Mch ≤ 1.075 mg; Subjects with FEV1 ≥ 70% of the predicted value at screening;
Subjects with occasional asthma symptoms (≤ 2 times/week), treated only with ICS-LABA inhalation (Symbicort®, budesonide and formoterol fumarate powder for inhalation, 1 inhalation per dose) as needed. The subject does not need to use other asthma medications on a daily basis, and other asthma medications have been discontinued before screening:
Inhaled and nasal should be discontinued for 4 weeks; Leukotriene receptor antagonists should be discontinued for 2 weeks; Long-acting β-receptor agonists should be discontinued for 2 weeks; Anticholinergic drugs should be discontinued for 2 weeks; Antihistamines should be discontinued for 2 weeks; Theophylline drugs should be discontinued for 1 week.
Exclusion Criteria:
Subjects who meet any of the following criteria must be excluded from this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who are enrolled in the study will be admitted to the study site on the day before each scheduled dose (D-1, D28, and D56) to complete the necessary pre-dose safety assessments and receive XKH001 subcutaneous (SC) injections on D1, D29, and D57.
Drug: XKH001 Injection
Dosage: 600 mg Q4W (D1, D29 and D57) Method of administration: the drug will be administered by SC injection in an area 3 cm away from and within 5 cm around the umbilicus of the abdomen. Sites with skin damage, inflammation, ulceration, rash and scar should be avoided. Subjects should be closely observed for reactions within 4 h after dosing.
To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.
Changes from baseline in FEV1 PD20 Mch after treatment
Time frame: Day43, Day85
To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.1
Incidence of AEs/SAEs
Time frame: Day169
To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.2
Severity of AEs/SAEs
Time frame: Day169
To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.1
Incidence of ADAs and NAb \[detect NAb when ADA positive\];
Time frame: Day169
To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.2
FeNO (exhaled nitric oxide concentration);
Time frame: Day169
To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.3
Total IgE;
Time frame: Day169
To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.4
Levels of IL-25-related cytokines in sputum supernatants (same as serum).
Time frame: Day169
To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.6
Cmax,ss,
Time frame: Day169
To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.7
Cmin,ss
Time frame: Day169
To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.8
Cavg,ss
Time frame: Day169
To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.9
AUC0-inf,ss
Time frame: Day169
To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.10
AUC0-t,ss,
Time frame: Day169
To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.11
Tmax,ss,
Time frame: Day169
To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.12
t1/2,ss
Time frame: Day169
To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.13
AUCtau,
Time frame: Day169
To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.14
%AUCex
Time frame: Day169
To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.15
λz,ss
Time frame: Day169
To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.36
Vz,ss/F
Time frame: Day169
To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.16
CLss/F
Time frame: Day169
To evaluate the effect on airway hyperresponsiveness and safety of multiple doses of XKH001 injection in patients with allergic asthma.17
MRT;
Time frame: Day169
To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.20
LYM ratios in sputum;
Time frame: Day169
To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.22
Whole blood EOS count
Time frame: Day169
To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.23
Whole blood NEU count
Time frame: Day169
To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.24
Whole blood LYM count
Time frame: Day169
To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.25
Whole blood MON count;
Time frame: Day169
To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.26
Levels of IL-25 in serum
Time frame: Day169
To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.27
Levels of TARC in serum
Time frame: Day169
To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.28
Levels of IL-8 in serum
Time frame: Day169
To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.29
Levels of MIP1β in serum
Time frame: Day169
To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.30
Levels of Eotaxin in serum
Time frame: Day169
To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.31
Levels of CXCL1 (KC/GROα) in serum
Time frame: Day169
To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.32
Levels of Eotaxin-3 in serum
Time frame: Day169
To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.33
Levels of IL-4 in serum
Time frame: Day169
To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.34
Levels of IL-5 in serum
Time frame: Day169
To evaluate the immunogenicity, PK characteristics, and PD characteristics of multiple doses of XKH001 injection in patients with allergic asthma.35
Levels of IL-13 in serum;
Time frame: Day169
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2023 to primary completion in Oct 2024, 9 months.
Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 9 months is above that.
Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: XKH001
Zhejiang Kanova Biopharmaceutical Co., LTD